Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer

被引：0
|
作者：
Kathryn Lurain
Ramya Ramaswami
Robert Yarchoan
Thomas S. Uldrick
机构：
[1] National Institutes of Health,HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
[2] Fred Hutchinson Cancer Research Center,Division of Global Oncology, Department of Medicine
[3] Fred Hutchinson Cancer Research Center,Vaccine and Infectious Disease Division
[4] Fred Hutchinson Cancer Research Center,Clinical Research Division
[5] University of Washington,Medical Oncology Division
来源：
Current HIV/AIDS Reports | 2020年 / 17卷
关键词：
PD-1; PD-L1; Checkpoint inhibitors; HIV; Cancer; T cell exhaustion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：547 / 556
页数：9
相关论文
共 50 条
  • [21] Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer
    Nakayama, Yuko
    Mimura, Kosaku
    Tamaki, Tomoaki
    Shiraishi, Kensuke
    Kua, Ley-Fang
    Koh, Vivien
    Ohmori, Masato
    Kimura, Ayako
    Inoue, Shingo
    Okayama, Hirokazu
    Suzuki, Yoshiyuki
    Nakazawa, Tadao
    Ichikawa, Daisuke
    Kono, Koji
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 54 (06) : 2030 - 2038
  • [22] Cimetidine Attenuates Therapeutic Effect of Anti-PD-1 and Anti-PD-L1 and Modulates Tumor Microenvironment in Colon Cancer
    Kuo, Feng-Chi
    Lai, Jerry Cheng-Yen
    Shieh, Hui-Ru
    Liou, Wan-Zu
    Bair, Ming-Jong
    Chen, Yu-Jen
    BIOMEDICINES, 2024, 12 (03)
  • [23] Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
    Schaberg, Kurt B.
    Novoa, Roberto A.
    Wakelee, Heather A.
    Kim, Jinah
    Cheung, Christine
    Srinivas, Sandhya
    Kwong, Bernice Y.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (04) : 339 - 346
  • [24] Experimental bladder cancer is eradicated by combined administration of CpG with anti-CTLA-4 or anti-PD-1, but not with anti-PD-L1
    Mangsbo, Sara
    Sadeghi, Arian
    Korman, Alan
    Loskog, Angelica
    Totterman, Thomas
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2008, 68 (02) : 212 - 212
  • [25] Dynamic changes of plasma PD-L1 mRNA expression is associated with anti-PD-1/anti-PD-L1 response in malignancies
    Yang, Q.
    Chen, M.
    Gu, J.
    Zheng, L.
    Yu, Y.
    Li, F.
    Zhang, L.
    Niu, K.
    Sun, J.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1777 - 1778
  • [26] Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment
    Passat, Tilda
    Touchefeu, Yann
    Gervois, Nadine
    Jarry, Anne
    Bossard, Celine
    Bennouna, Jaafar
    BULLETIN DU CANCER, 2018, 105 (11) : 1033 - 1041
  • [27] Anti-PD-1 monoclonal antibody Cancer immunotherapy
    da Silva, R. Moreira
    DRUGS OF THE FUTURE, 2014, 39 (01) : 15 - 24
  • [28] Granulomatous myositis induced by anti-PD-1 monoclonal antibodies
    Uchio, Naohiro
    Taira, Kenichiro
    Ikenaga, Chiseko
    Unuma, Atsushi
    Kadoya, Masato
    Kubota, Akatsuki
    Toda, Tatsushi
    Shimizu, Jun
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2018, 5 (04):
  • [29] In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
    Aspeslagh, Sandrine
    Matias, Margarida
    Palomar, Virginia
    Dercle, Laurent
    Lanoy, Emilie
    Soria, Jean-Charles
    Postel-Vinay, Sophie
    EUROPEAN JOURNAL OF CANCER, 2017, 87 : 65 - 74
  • [30] Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer
    Shukuya, Takehito
    Carbone, David P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 976 - 988
12345